Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AC Immune stock logo
ACIU
AC Immune
$2.04
-3.3%
$1.86
$1.43
$4.26
$211.87M1.62143,170 shs86,216 shs
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
$729.62
-0.5%
$750.64
$279.02
$830.21
$57.06B1.29545,551 shs1.12 million shs
Clovis Oncology stock logo
CLVS
Clovis Oncology
$0.43
$0.08
$3.32
$11.60M0.248.88 million shs1.16 million shs
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
$31.93
-0.2%
$30.96
$24.10
$62.53
$3.00B0.25821,194 shs598,277 shs
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
$6.28
-1.3%
$6.07
$5.41
$23.48
$550.61M0.41.27 million shs1.20 million shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AC Immune stock logo
ACIU
AC Immune
+1.44%+2.43%-4.09%+35.26%-38.84%
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
-9.04%-7.86%-3.89%+29.05%+149.92%
Clovis Oncology stock logo
CLVS
Clovis Oncology
0.00%0.00%0.00%0.00%0.00%
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
-1.05%+7.08%-3.30%+9.89%-37.03%
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
+3.25%+7.61%-6.61%+10.23%-68.72%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AC Immune stock logo
ACIU
AC Immune
2.3408 of 5 stars
3.51.00.00.03.70.80.6
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
2.0964 of 5 stars
2.43.00.00.04.12.50.0
Clovis Oncology stock logo
CLVS
Clovis Oncology
N/AN/AN/AN/AN/AN/AN/AN/A
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
3.4846 of 5 stars
3.40.00.03.72.52.50.0
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
4.5084 of 5 stars
4.42.00.04.72.80.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AC Immune stock logo
ACIU
AC Immune
3.00
Buy$12.00488.24% Upside
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
2.77
Moderate Buy$699.55-4.12% Downside
Clovis Oncology stock logo
CLVS
Clovis Oncology
0.00
N/AN/AN/A
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
2.80
Moderate Buy$69.50117.66% Upside
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
2.86
Moderate Buy$24.50290.13% Upside

Current Analyst Ratings Breakdown

Latest KURA, ACIU, AXON, CLVS, and CRNX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/10/2025
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$36.00
7/7/2025
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform
6/27/2025
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$81.00
6/26/2025
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight
6/20/2025
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$36.00
6/4/2025
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$750.00 ➝ $895.00
6/4/2025
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$28.00
5/19/2025
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$32.00 ➝ $30.00
5/14/2025
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$730.00 ➝ $830.00
5/9/2025
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$726.00 ➝ $735.00
5/8/2025
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$600.00 ➝ $750.00
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AC Immune stock logo
ACIU
AC Immune
$31.02M6.60N/AN/A$1.29 per share1.58
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
$2.08B27.27$2.77 per share263.10$30.52 per share23.91
Clovis Oncology stock logo
CLVS
Clovis Oncology
$148.76M0.00N/AN/A($2.15) per share0.00
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
$1.04M2,874.62N/AN/A$14.29 per share2.23
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
$53.88M10.09N/AN/A$5.32 per share1.18
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AC Immune stock logo
ACIU
AC Immune
-$57.83M-$0.580.00N/AN/A-177.79%-44.60%-22.25%8/5/2025 (Estimated)
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
$377.03M$4.14449.69219.1184.3714.86%5.81%2.83%8/5/2025 (Estimated)
Clovis Oncology stock logo
CLVS
Clovis Oncology
-$264.52M-$1.83N/AN/AN/A-189.37%N/A-57.78%N/A
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
-$298.41M-$3.82N/AN/AN/AN/A-30.95%-28.12%8/6/2025 (Estimated)
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
-$173.98M-$2.100.00N/AN/AN/A-43.62%-29.13%8/6/2025 (Estimated)

Latest KURA, ACIU, AXON, CLVS, and CRNX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
AC Immune stock logo
ACIU
AC Immune
-$0.18N/AN/AN/A$1.98 millionN/A
8/5/2025Q2 2025
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
$1.54N/AN/AN/A$641.77 millionN/A
5/8/2025Q1 2025
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
-$0.99-$1.04-$0.05-$1.04$0.10 million$0.36 million
5/7/2025Q1 2025
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
$1.34$1.41+$0.07$1.08$585.67 million$603.63 million
5/1/2025Q1 2025
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
-$0.51-$0.66-$0.15-$0.66$39.08 million$14.11 million
4/30/2025Q1 2025
AC Immune stock logo
ACIU
AC Immune
-$0.22-$0.21+$0.01-$0.21$1.99 million$1.12 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AC Immune stock logo
ACIU
AC Immune
N/AN/AN/AN/AN/A
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
N/AN/AN/AN/AN/A
Clovis Oncology stock logo
CLVS
Clovis Oncology
N/AN/AN/AN/AN/A
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
N/AN/AN/AN/AN/A
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AC Immune stock logo
ACIU
AC Immune
N/A
1.53
1.53
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
0.68
2.83
2.62
Clovis Oncology stock logo
CLVS
Clovis Oncology
N/A
0.14
0.12
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
N/A
22.53
22.53
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
0.02
8.07
8.07

Institutional Ownership

CompanyInstitutional Ownership
AC Immune stock logo
ACIU
AC Immune
51.36%
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
79.08%
Clovis Oncology stock logo
CLVS
Clovis Oncology
24.53%
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
98.51%
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
N/A

Insider Ownership

CompanyInsider Ownership
AC Immune stock logo
ACIU
AC Immune
4.60%
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
4.40%
Clovis Oncology stock logo
CLVS
Clovis Oncology
4.40%
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
4.60%
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
6.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
AC Immune stock logo
ACIU
AC Immune
140100.41 million95.79 millionOptionable
Axon Enterprise, Inc stock logo
AXON
Axon Enterprise
4,97077.85 million74.43 millionOptionable
Clovis Oncology stock logo
CLVS
Clovis Oncology
N/A144.96 million138.58 millionOptionable
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
21093.63 million89.32 millionOptionable
Kura Oncology, Inc. stock logo
KURA
Kura Oncology
13086.57 million81.03 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AC Immune stock logo

AC Immune NASDAQ:ACIU

$2.04 -0.07 (-3.32%)
Closing price 04:00 PM Eastern
Extended Trading
$2.05 +0.01 (+0.49%)
As of 04:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Axon Enterprise stock logo

Axon Enterprise NASDAQ:AXON

$729.62 -3.37 (-0.46%)
As of 04:00 PM Eastern

Axon Enterprise, Inc. develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence. Its products include axon officer safety plan; taser 10, taser7, taser X26P, taser X2, taser 7 CQ, and civilian series; cameras, such as axon body, axon flex, axon fleet, axon air, axon signal sidearm, axon signal vehicle, axon interview, and axon interview portable kit; software, including axon records, evidence, standards, commander, performance, auto-transcribe, justice, investigate, respond, and justice, my90, and redaction assistant; mobile applications, and training services, as well as hardware extended warranties; and Axon docks, cartridges, and batteries. The company sells its products through its direct sales, distribution partners, online store, and third-party resellers. Axon Enterprise, Inc. has a strategic partnership with Fusus, Inc. to expand bility to aggregate live video, data, and sensor feeds. It serves law enforcement, federal, correction, fire, EMS, campus, justice healthcare, retail, private security, and personal safety industries. The company was formerly known as TASER International, Inc. and changed its name to Axon Enterprise, Inc. in April 2017. Axon Enterprise, Inc. was incorporated in 1993 and is headquartered in Scottsdale, Arizona.

Clovis Oncology stock logo

Clovis Oncology NASDAQ:CLVS

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.

Crinetics Pharmaceuticals stock logo

Crinetics Pharmaceuticals NASDAQ:CRNX

$31.93 -0.06 (-0.19%)
Closing price 04:00 PM Eastern
Extended Trading
$31.92 0.00 (-0.02%)
As of 05:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Kura Oncology stock logo

Kura Oncology NASDAQ:KURA

$6.28 -0.08 (-1.26%)
Closing price 04:00 PM Eastern
Extended Trading
$6.28 +0.00 (+0.08%)
As of 06:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.